Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia  Pablo Lázaro, MD, PhD, MBA, Leopoldo Pérez.

Slides:



Advertisements
Similar presentations
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
Advertisements

Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms Iván Álvarez-Twose,
Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial  Arja T. Erkkilä, PhD, Ursula.
Health Benefits of Nordic Walking
Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements 
Hypertension-Lipid Connection: Introduction
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
Manuel J. Antunes, MD, PhD, DSc 
Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.
The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data  Steve E. Humphries, PhD, FRCP, Jackie Cooper,
Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
An assessment by the Statin Cognitive Safety Task Force: 2014 update
An assessment by the Statin Muscle Safety Task Force: 2014 update
An assessment by the Statin Liver Safety Task Force: 2014 update
Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.
Walking Recovery After an Acute Stroke: Assessment With a New Functional Classification and the Barthel Index  Enrique Viosca, PhD, MD, Rubén Lafuente,
Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,
A review of PCSK9 inhibition and its effects beyond LDL receptors
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.
Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome  Richard M. Turner,
Normal Weight-Central Obesity Is Associated with the Highest Mortality Risk in Older Adults with Coronary Artery Disease*†  Saurabh Sharma, MD, John A.
Predictors of first-year statin medication discontinuation: A cohort study  Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,
Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial  Arja T. Erkkilä, PhD, Ursula.
The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data  Steve E. Humphries, PhD, FRCP, Jackie Cooper,
A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia  Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.
Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B
J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A
Temporal Trends in Lipid Screening for Familial Hypercholesterolemia in Youth  Catherine J. McNeal, MD, PhD, Justin Zachariah, MD, MPH, Laurel Copeland,
Meredith Kilgore, PhD, Paul Muntner, PhD, J
Emma J. Aarnio, MSc (Pharm), Janne A
Lysosomal acid lipase deficiency: A hidden disease among cohorts of familial hypercholesterolemia?  Joana Rita Chora, MSc, Ana Catarina Alves, PhD, Ana.
William L. Gerald, M.D., Ph.D, 1954–2008
Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M
Temporal Trends in Lipid Screening for Familial Hypercholesterolemia in Youth  Catherine J. McNeal, MD, PhD, Justin Zachariah, MD, MPH, Laurel Copeland,
Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial  James D. Otvos,
Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1  Omar Abdel-Razek, MD, Singh N.
Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.
An assessment by the Statin Intolerance Panel: 2014 update
Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis 
Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States  Sudhir K. Unni, PhD, MBA, Ruben G.W.
Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia  Andrew G. Bostom,
Simplified Canadian Definition for Familial Hypercholesterolemia
Ahmed Kayssi, MD, MSc, MPH, Charles de Mestral, MD CM, PhD, Thomas L
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
A Recurrent Cause of Upper Gastrointestinal Bleeding: Gastritis Diagnoses Are Not All Trivial  Javier Martínez-González, Ana García García de Paredes,
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia  G. Kees Hovingh, MD,
The lord of the rings  Antonio Miceli, MD, PhD 
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia  Merel L. Hartgers, MD, Joep.
Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia  Raul D. Santos, Frederick J. Raal,
Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A
Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients  Alberto Zamora,
Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical.
Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT.
Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms  Iván Álvarez-Twose,
Table of contents The Journal for Nurse Practitioners
Christopher S. Penet, Brian H. Annex, MD, Kelly T. Gregory, R
Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia  Martine Paquette, MSc, Sophie.
Anaphylaxis epidemiology in patients with and patients without asthma: A United Kingdom database review  Antonio González-Pérez, BPharm, MS, Zuleika Aponte,
Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review  Ilse K. Luirink, MD, Jim.
Higher long-term adherence to statins in rural patients at high atherosclerotic risk  Matthew R. Peverelle, MD, BBiomed, Arul Baradi, MBChB, Sarang Paleri,
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.
Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?*  Anna.
News Beyond Our Pages Journal of Allergy and Clinical Immunology
Urbanization, mainly rurality, but not altitude is associated with dyslipidemia profiles  Maria Lazo-Porras, Antonio Bernabe-Ortiz, Renato Quispe, German.
Prediction of Cardiovascular Disease Events by Lipoprotein(a) According to LDL-C in Older High Risk Adults  Nathan D. Wong, PhD, Shravanthi R. Gandra,
LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design  Dirk J. Blom, MD, PhD, Zahi A. Fayad,
Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia  Anna.
News & Notes Journal of Allergy and Clinical Immunology
Presentation transcript:

Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia  Pablo Lázaro, MD, PhD, MBA, Leopoldo Pérez de Isla, MD, PhD, Gerald F. Watts, DSc, MD, Rodrigo Alonso, MD, PhD, Richard Norman, PhD, MSc, Ovidio Muñiz, MD, PhD, Francisco Fuentes, MD, PhD, Nelva Mata, MD, PhD, José López-Miranda, MD, PhD, José Ramón González-Juanatey, MD, PhD, José Luis Díaz-Díaz, MD, PhD, Antonio Javier Blasco, MPH, PhD, Pedro Mata, MD, PhD  Journal of Clinical Lipidology  Volume 11, Issue 1, Pages 260-271 (January 2017) DOI: 10.1016/j.jacl.2017.01.002 Copyright © 2017 National Lipid Association Terms and Conditions

Figure 1 Decision tree structure (simplified) for the model. Journal of Clinical Lipidology 2017 11, 260-271DOI: (10.1016/j.jacl.2017.01.002) Copyright © 2017 National Lipid Association Terms and Conditions

Figure 2 Diagnostic tests results in index cases and relatives. Journal of Clinical Lipidology 2017 11, 260-271DOI: (10.1016/j.jacl.2017.01.002) Copyright © 2017 National Lipid Association Terms and Conditions

Figure 3 Incremental cost-utility ratio (cost per QALY gained) of the NPFH implementation considering the payer and social perspectives: sensitivity analysis. Journal of Clinical Lipidology 2017 11, 260-271DOI: (10.1016/j.jacl.2017.01.002) Copyright © 2017 National Lipid Association Terms and Conditions